# Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder Cancer

> **NCT05535218** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Claudia Guerrieri** · enrollment: 48 (estimated)

## Conditions studied

- Muscle-invasive Urothelial Carcinoma of the Bladder

## Interventions

- **DRUG:** Sacituzumab govitecan is a humanized mAb with a hydrolysable linker through which SN-38 is conjugated to the humanized mAb hRS7 IgG1κ to enhance the delivery of SN-38 to Trop-2- expressing tumors, whi

## Key facts

- **NCT ID:** NCT05535218
- **Lead sponsor:** Claudia Guerrieri
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-20
- **Primary completion:** 2027-02
- **Final completion:** 2027-02
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05535218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05535218, "Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05535218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*